Compare SYNA & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYNA | WVE |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2002 | 2015 |
| Metric | SYNA | WVE |
|---|---|---|
| Price | $89.27 | $13.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $92.67 | $29.94 |
| AVG Volume (30 Days) | 700.4K | ★ 4.1M |
| Earning Date | 02-05-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,109,100,000.00 | $109,230,000.00 |
| Revenue This Year | $12.07 | N/A |
| Revenue Next Year | $10.05 | $16.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.24 | ★ 103.75 |
| 52 Week Low | $41.80 | $5.28 |
| 52 Week High | $94.59 | $21.73 |
| Indicator | SYNA | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 46.61 |
| Support Level | $85.08 | $13.22 |
| Resistance Level | $94.59 | $15.97 |
| Average True Range (ATR) | 4.11 | 1.35 |
| MACD | 0.60 | -0.44 |
| Stochastic Oscillator | 73.45 | 11.54 |
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.